Cancer patients' trade-offs among efficacy, toxicity, and out-of-pocket cost in the curative and noncurative setting

Medical Care

Volumn 51, Issue 9, 2013, Pages 838-845

  Wong, Yu Ning ^a   Egleston, Brian L ^a   Sachdeva, Kush ^b   Eghan, Naa ^c   Pirollo, Melanie ^b   Stump, Tammy K ^d   Beck, John Robert ^a   Armstrong, Katrina ^e   Schwartz, Jerome Sanford ^e   Meropol, Neal J ^f  

^a FOX CHASE CANCER CENTER   (United States)

^b South Jersey Healthcare   (United States)

^c Premier Research   (United States)

^d UNIVERSITY OF UTAH   (United States)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

^f UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

Cancer; Decision making; Health economics

Indexed keywords

ADULT; AGED; ARTICLE; AVERSION THERAPY; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER SURVIVAL; CHRONIC TOXICITY; COMMUNITY HOSPITAL; COST OF ILLNESS; EDUCATION; EMPLOYMENT STATUS; FEMALE; HEALTH CARE COST; HEALTH ECONOMICS; HEALTH INSURANCE; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; PATIENT DECISION MAKING; PATIENT PREFERENCE; PRIORITY JOURNAL; SOCIAL STATUS;

ADULT; AGED; AGED, 80 AND OVER; COST-BENEFIT ANALYSIS; DECISION MAKING; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PATIENT PREFERENCE; QUALITY OF LIFE; SOCIOECONOMIC FACTORS;

EID: 84883244153     PISSN: 00257079     EISSN: 15371948     Source Type: Journal    
DOI: 10.1097/MLR.0b013e31829faffd     Document Type: Article

References (33)

1. Andre T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004;350: 2343-2351.
2. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005;353: 1659-1672.
3. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006;355: 2542-2550.
4. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356: 125-134.
5. Carroll J. When new drugs are costly, how high to raise copays? Manag Care. 2006. Available: http://www.managedcaremag.com/archives/0606/0606.tiers. html.
6. Meropol NJ, Schrag D, Smith TJ, et al. American Society of Clinical Oncology Guidance Statement: The Cost of Cancer Care. J Clin Oncol. 2009;27: 3868-3874.
7. Schrag D, Hanger M. Medical oncologists' views on communicating with patients about chemotherapy costs: a pilot survey. J Clin Oncol. 2007;25: 233-237.
8. Newhouse JP, Manning WG, Morris CN, et al. Some interim results from a controlled trial of cost sharing in health insurance. N Engl J Med. 1981;305: 1501-1507.
9. Katz JN. Patient preferences and health disparities. JAMA. 2001;286: 1506-1509.
10. de Bekker-Grob EW, Ryan M, Gerard K. Discrete choice experiments in health economics: a review of the literature. Health Econ. 2012;21: 145-172.
11. Ryan M, Farrar S. Using conjoint analysis to elicit preferences for health care. BMJ. 2000;320: 1530-1533.
12. Fagerlin A, Zikmund-Fisher BJ, Ubel PA, et al. Measuring numeracy without a math test: development of the Subjective Numeracy Scale. Med Decis Making. 2007;27: 672-680.
13. Scheier MF, Carver CS. Optimism, coping, and health: assessment and implications of generalized outcome expectancies. Health Psychol. 1985;4: 219-247.
14. Agresti A. Categorical Data Analysis. Hoboken, NJ: John Wiley and Sons; 2002.
15. Liang K, Zeger S. Multivariate regression analyses for categorical data. J R Stat Soc. 1992;B54: 3-40.
16. Reboussin BA, Song EY, Shrestha A, et al. A latent class analysis of underage problem drinking: evidence from a community sample of 16-20 year olds. Drug Alcohol Depend. 2006;83: 199-209.
17. Thacher JA, Morey E, Craighead WE. Using patient characteristics and attitudinal data to identify depression treatment preference groups: a latent-class model. Depress Anxiety. 2005;21: 47-54.
18. Skrondal A, Rabe-Hesketh S. Generalized Latent Variable Modeling: Multilevel, Longitudinal, and Structural Equation Models. Boca Raton, FL: Chapman & Hall/CRC; 2004.
19. Vig HS, Armstrong J, Egleston BL, et al. Cancer genetic risk assessment and referral patterns in primary care. Genet Test Mol Biomarkers. 2009;13: 735-741.
20. Coffman DL, Patrick ME, Palen LA, et al. Why do high school seniors drink? Implications for a targeted approach to intervention. Prev Sci. 2007;8: 241-248.
21. Sutfin EL, Reboussin BA, McCoy TP, et al. Are college student smokers really a homogeneous group? A latent class analysis of college student smokers. Nicotine Tob Res. 2009;11: 444-454.
22. Blinman P, Alam M, Duric V, et al. Patients' preferences for chemotherapy in non-small-cell lung cancer: a systematic review. Lung Cancer. 2010;69: 141-147.
23. Goldman DP, Joyce GF, Zheng Y. Prescription drug cost sharing: associations with medication and medical utilization and spending and health. JAMA. 2007;298: 61-69.
24. Lakdawalla DN, Romley JA, Sanchez Y, et al. How cancer patients value hope and the implications for cost-effectiveness assessments of high-cost cancer therapies. Health Aff (Millwood). 2012;31: 676-682.
25. Neugut AI, Subar M, Wilde ET, et al. Association between prescription co-payment amount and compliance with adjuvant hormonal therapy in women with early-stage breast cancer. J Clin Oncol. 2011;29: 2534-2542.
26. Streeter SB, Schwartzberg L, Husain N, et al. Patient and plan characteristics affecting abandonment of oral oncolytic prescriptions. Am J Manag Care. 2011;17(suppl 5 Developing):SP38-SP44.
27. Zafar SY, Peppercorn JM, Schrag D, et al. The financial toxicity of cancer treatment: a pilot study assessing out-of-pocket expenses and the insured cancer patient's experience. Oncologist. 2013;18: 381-390.
28. Wong YN, Hamilton O, Egleston B, et al. Understanding how out-ofpocket expenses, treatment value, and patient characteristics influence treatment choices. Oncologist. 2010;15: 566-576.
29. Nathan H, Bridges JFP, Schulick RD, et al. Understanding surgical decision making in early hepatocellular carcinoma. J Clin Oncol. 2011; 29: 619-625.
30. Casarett DJ, Fishman JM, Lu HL, et al. The terrible choice: re-evaluating hospice eligibility criteria for cancer. J Clin Oncol. 2009;27: 953-959.
31. Epstein RM, Gramling RE. What is shared in shared decision making? complex decisions when the evidence is unclear. Med Care Res Rev. 2013;70: 94S-112S.
32. Selby JV, Beal AC, Frank L. The patient-centered outcomes research institute (PCORI) national priorities for research and initial research agenda. JAMA. 2012;307: 1583-1584.
33. de Souza JA, Ratain MJ, Fendrick AM. Value-based insurance design: aligning incentives, benefits, and evidence in oncology. J Ntl Compr Cancer Netw. 2012;10: 18-23.